Not every ticker in a healthcare-and-technology screen actually belongs to a drug developer or a software firm. Circle8 Group, Inc. (NASDAQ: CIRC) is a reminder of that: despite serving technology and finance clients, the company is a staffing and workforce-solutions provider, not a health …
Among the smallest names in the gene-therapy landscape, Calidi Biotherapeutics, Inc. (NYSE American: CLDI) commands attention less for its size than for the ambition of its science. With a marketCapitalizationof only a few million dollars and shares near $1.36 following a mid-year reverse split, …
CollPlant Biotechnologies Ltd (NASDAQ:CLGN) is a case study in promising science meeting hard commercial reality. The Israeli regenerative-medicine company builds products from plant-derived recombinant human collagen (rhCollagen), but through 2026 it has been cutting costs, exploring strategic alternatives and raising small amounts of capital.
● Clene sits at one of the more closely followed inflection points in neurodegeneration research, where a small-cap developer is trying to convert years of biomarker data into an actual regulatory filing.
On a percentage basis, a jump from $0.0001 to $0.0002 looks explosive, a clean 100% gain. In practice it is a single sub-penny tick in a stock that its own company pulled from public markets. That is the situation confronting Biostax Corp. (OTC:BTAX), a …
Few companies embodied the early promise of prescription digital therapeutics as vividly as Better Therapeutics, Inc (OTC:BTTX), and few have fallen as far. Once a Nasdaq-listed developer of software-based treatments for chronic disease, Better Therapeutics now trades as a dormant sub-penny relic.
The ticker tells much of the story before any analysis begins. Baudax Bio, Inc (OTC:BXRXQ) now trades under a symbol whose trailing Q is the market's shorthand for a company in, or associated with,Bankruptcyproceedings. Quoted at a fraction of a cent with aMarket Valuemeasured …
● What is verifiable is a steady stream of activity: on 27 August 2026 Caris published a study in npj Precision Oncology indicating AI-guided therapy selection was associated with longer survival in pancreatic cancer patients, on 2 September it said it would present research …
Priced in fractions of a cent and valued at roughly a million dollars, China Dongsheng International, Inc (OTC: CDSG) is a classic sub-penny shell stock, and one whoseBusinessbears little resemblance to what its name suggests. Rather than a Chinese health-products enterprise, CDSG today is …
CDT Equity Inc (NASDAQ:CDT) is a company in the middle of reinventing itself, so much so that its name changed in 2026. Formerly Conduit Pharmaceuticals, the micro-cap has broadened well beyond its original drug-development roots, adding investments in areas as varied as peptides and …